Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980472 | 0.84 | MAOB (0.53) | PDE4BMAOBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL981836 | 0.77 | MAOB (0.43) | PDE4BMAOBSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL981645 | 0.72 | MAOB (0.35) | MAOBSMN1; SMN2HTTKDM4EALDH1A1 | |
| SCHEMBL979919 | 0.70 | SMN1; SMN2 (0.48) | PDE4BMAOBSMN1; SMN2HTTKDM4E | |
| SCHEMBL14487686 | 0.70 | PDE4B (0.51) | PDE4BMAOBSMN1; SMN2HTTKDM4E | |
| SCHEMBL979918 | 0.67 | PDE4B (0.44) | PDE4BMAOBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL979450 | 0.67 | PGR (0.38) | MAOBSMN1; SMN2ALDH1A1HPGDPKM | |
| SCHEMBL14553572 | 0.66 | KMT2A (0.57) | PDE4BMAOBHTTPDE4D | |
| SCHEMBL980162 | 0.66 | JAK2 (0.36) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL14487421 | 0.66 | PDE4B (0.49) | PDE4BMAOBSMN1; SMN2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917248-B1 | 1-ACYLDIHYDROPYRAZOL DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-08-19 | — | — | EP | claimed |
| EP-1917248-B1 | 1-ACYLDIHYDROPYRAZOL DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-7875644-B2 | tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas | MERCK PATENT GMBH (DE) | 2011-01-25 | — | — | US | disclosed |
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MET, FLT3, ERBB3 | PDE4B 2615/4885MAOB 1138/4885SMN1; SMN2 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.